Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
- 1 January 2017
- journal article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 169, 35-46
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3American Journal of Respiratory and Critical Care Medicine, 2012
- Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated miceJournal of Experimental Medicine, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- A CommonMUC5BPromoter Polymorphism and Pulmonary FibrosisNew England Journal of Medicine, 2011
- Gene Expression Profiles of Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio‐marker of fibroproliferative disease?Journal of Cell Communication and Signaling, 2009
- Pulmonary fibrosis: pathogenesis, etiology and regulationMucosal Immunology, 2009
- Alternative activation of macrophagesNature Reviews Immunology, 2003